fda compounding semaglutide crackdown news today Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots US FDA sends 25 letters

Major weight loss, pain relief seen with Eli Lilly's next-gen drug in late-stage trial Retatrutide reduced knee pain by up to 75.8% in late-stage trial A new weight-loss drug that Eli Lilly is testing is helping patients in a late-stage trial lose an average of 28.7% of their body weight and offered "substantial" relief from osteoarthritis pain

This mechanical unloading can translate into meaningful symptom improvement, as supported by the American College of Rheumatology guidelines

Its ability to promote weight loss can also alleviate obesity-related stress on the kidneys, improving overall kidney function

We just need to give them the right conditions to do so

Weight loss plateaus are a normal part of the process reflecting metabolic adaptation, not medication failure

Retatrutide produces greater blood pressure reduction than semaglutide